Does the media refer more to MDAI or NMTC?

In the previous week, Spectral AI and Spectral AI both had 1 articles in the media. NeuroOne Medical Technologies' average media sentiment score of 0.33 beat Spectral AI's score of 0.20 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spectral AI 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SRTS or NMTC?

In the previous week, Sensus Healthcare and Sensus Healthcare both had 1 articles in the media. Sensus Healthcare's average media sentiment score of 0.59 beat NeuroOne Medical Technologies' score of 0.33 indicating that Sensus Healthcare is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensus Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NMTC or POCI?

In the previous week, Precision Optics had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Precision Optics and 1 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.33 beat Precision Optics' score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precision Optics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TELA or NMTC?

In the previous week, TELA Bio had 8 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 9 mentions for TELA Bio and 1 mentions for NeuroOne Medical Technologies. TELA Bio's average media sentiment score of 1.42 beat NeuroOne Medical Technologies' score of 0.33 indicating that TELA Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TELA Bio 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BDMD or NMTC?

NeuroOne Medical Technologies has a consensus price target of $7.33, indicating a potential upside of 427.58%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Baird Medical Investment. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Baird Medical Investment 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroOne Medical Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger earnings & valuation, BDMD or NMTC?

Baird Medical Investment has higher revenue and earnings than NeuroOne Medical Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Baird Medical Investment $22.54M 1.97 N/A N/A N/A NeuroOne Medical Technologies $12.10M 1.05 -$3.61M -$0.95 N/A

NeuroOne Medical Technologies (NMTC) Competitors

$1.39 +0.03 (+2.21%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.38 -0.01 (-1.08%)

As of 09/18/2026 07:30 PM Eastern

Compare

NMTC vs. MDAI, SRTS, POCI, TELA, and BDMD

Should you buy NeuroOne Medical Technologies stock or one of its competitors? NeuroOne Medical Technologies's main competitors and comparable companies include Spectral AI (MDAI), Sensus Healthcare (SRTS), Precision Optics (POCI), TELA Bio (TELA), and Baird Medical Investment (BDMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does NeuroOne Medical Technologies compare to Spectral AI?

Spectral AI (NASDAQ:MDAI) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Spectral AI has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Spectral AI currently has a consensus target price of $4.00, indicating a potential upside of 143.90%. NeuroOne Medical Technologies has a consensus target price of $7.33, indicating a potential upside of 427.58%. Given NeuroOne Medical Technologies' higher probable upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Spectral AI and Spectral AI both had 1 articles in the media. NeuroOne Medical Technologies' average media sentiment score of 0.33 beat Spectral AI's score of 0.20 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroOne Medical Technologies has lower revenue, but higher earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	2.69	-$7.57M	-$0.35	N/A
NeuroOne Medical Technologies	$12.10M	1.05	-$3.61M	-$0.95	N/A

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 13.7% of Spectral AI shares are owned by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Spectral AI has a net margin of -69.27% compared to NeuroOne Medical Technologies' net margin of -71.50%. Spectral AI's return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-69.27%	N/A	-78.56%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

Summary

Spectral AI beats NeuroOne Medical Technologies on 11 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Sensus Healthcare?

Sensus Healthcare (NASDAQ:SRTS) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Sensus Healthcare and Sensus Healthcare both had 1 articles in the media. Sensus Healthcare's average media sentiment score of 0.59 beat NeuroOne Medical Technologies' score of 0.33 indicating that Sensus Healthcare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensus Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sensus Healthcare presently has a consensus price target of $5.83, indicating a potential upside of 91.26%. NeuroOne Medical Technologies has a consensus price target of $7.33, indicating a potential upside of 427.58%. Given NeuroOne Medical Technologies' higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Sensus Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensus Healthcare	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

NeuroOne Medical Technologies has lower revenue, but higher earnings than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensus Healthcare	$27.48M	1.83	-$7.72M	-$0.94	N/A
NeuroOne Medical Technologies	$12.10M	1.05	-$3.61M	-$0.95	N/A

NeuroOne Medical Technologies has a net margin of -71.50% compared to Sensus Healthcare's net margin of -88.45%. Sensus Healthcare's return on equity of -21.57% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensus Healthcare	-88.45%	-21.57%	-19.20%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 10.2% of Sensus Healthcare shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sensus Healthcare has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Summary

Sensus Healthcare beats NeuroOne Medical Technologies on 10 of the 15 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Precision Optics?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Precision Optics (NASDAQ:POCI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Precision Optics has a net margin of -17.03% compared to NeuroOne Medical Technologies' net margin of -71.50%. Precision Optics' return on equity of -37.47% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%
Precision Optics	-17.03%	-37.47%	-19.96%

NeuroOne Medical Technologies has higher earnings, but lower revenue than Precision Optics. Precision Optics is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	1.05	-$3.61M	-$0.95	N/A
Precision Optics	$19.09M	2.56	-$5.78M	-$0.63	N/A

NeuroOne Medical Technologies has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Precision Optics has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

In the previous week, Precision Optics had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Precision Optics and 1 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.33 beat Precision Optics' score of 0.00 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision Optics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroOne Medical Technologies presently has a consensus target price of $7.33, suggesting a potential upside of 427.58%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe NeuroOne Medical Technologies is more favorable than Precision Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Precision Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 13.7% of Precision Optics shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Comparatively, 14.4% of Precision Optics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

NeuroOne Medical Technologies and Precision Optics tied by winning 8 of the 16 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

TELA Bio has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

TELA Bio has a net margin of -51.53% compared to NeuroOne Medical Technologies' net margin of -71.50%. NeuroOne Medical Technologies' return on equity of -128.12% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

NeuroOne Medical Technologies has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.70	-$38.83M	-$0.77	N/A
NeuroOne Medical Technologies	$12.10M	1.05	-$3.61M	-$0.95	N/A

In the previous week, TELA Bio had 8 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 9 mentions for TELA Bio and 1 mentions for NeuroOne Medical Technologies. TELA Bio's average media sentiment score of 1.42 beat NeuroOne Medical Technologies' score of 0.33 indicating that TELA Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TELA Bio	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TELA Bio presently has a consensus target price of $2.20, indicating a potential upside of 76.00%. NeuroOne Medical Technologies has a consensus target price of $7.33, indicating a potential upside of 427.58%. Given NeuroOne Medical Technologies' higher probable upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 5.1% of TELA Bio shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

TELA Bio beats NeuroOne Medical Technologies on 8 of the 14 factors compared between the two stocks.

How does NeuroOne Medical Technologies compare to Baird Medical Investment?

Baird Medical Investment (NASDAQ:BDMD) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Baird Medical Investment has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -71.50%. Baird Medical Investment's return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baird Medical Investment	N/A	N/A	N/A
NeuroOne Medical Technologies	-71.50%	-128.12%	-86.34%

NeuroOne Medical Technologies has a consensus price target of $7.33, indicating a potential upside of 427.58%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts clearly believe NeuroOne Medical Technologies is more favorable than Baird Medical Investment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baird Medical Investment	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Baird Medical Investment has a beta of -1.15, indicating that its stock price is 215% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

In the previous week, Baird Medical Investment had 3 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 4 mentions for Baird Medical Investment and 1 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.33 beat Baird Medical Investment's score of -0.25 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baird Medical Investment	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Baird Medical Investment has higher revenue and earnings than NeuroOne Medical Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baird Medical Investment	$22.54M	1.97	N/A	N/A	N/A
NeuroOne Medical Technologies	$12.10M	1.05	-$3.61M	-$0.95	N/A

Summary

Baird Medical Investment beats NeuroOne Medical Technologies on 8 of the 13 factors compared between the two stocks.

Get NeuroOne Medical Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NMTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NMTC vs. The Competition

Export

Metric	NeuroOne Medical Technologies	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.66M	$5.55B	$7.24B	$13.19B
Dividend Yield	N/A	1.80%	2.57%	12.81%
P/E Ratio	-1.46	25.34	275.49	25.40
Price / Sales	1.05	72.49	646.01	89.45
Price / Cash	N/A	32.64	76.25	51.42
Price / Book	1.64	5.69	10.46	6.33
Net Income	-$3.61M	$151.55M	$3.49B	$358.33M
7 Day Performance	-10.90%	0.66%	0.59%	1.12%
1 Month Performance	-35.35%	-3.33%	-1.74%	-2.39%
1 Year Performance	-75.09%	6.79%	18.13%	5.35%

NeuroOne Medical Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NMTC NeuroOne Medical Technologies	3.1629 of 5 stars	$1.39 +2.2%	$7.33 +427.6%	-75.1%	$12.66M	$12.10M	N/A	18	News Coverage Gap Up
MDAI Spectral AI	1.7435 of 5 stars	$1.59 -1.2%	$4.00 +151.6%	-32.0%	$51.82M	$19.65M	N/A	83	Analyst Upgrade
SRTS Sensus Healthcare	3.0868 of 5 stars	$3.08 -1.6%	$5.83 +89.4%	-1.9%	$51.53M	$27.48M	N/A	40
POCI Precision Optics	0.503 of 5 stars	$4.21 -3.0%	N/A	+2.5%	$47.50M	$19.09M	N/A	80	News Coverage Upcoming Earnings Short Interest Decrease
TELA TELA Bio	4.1081 of 5 stars	$1.09 +4.8%	$2.20 +101.8%	-22.8%	$46.69M	$80.28M	N/A	120	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NMTC) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroOne Medical Technologies (NMTC) Competitors

NMTC vs. MDAI, SRTS, POCI, TELA, and BDMD

How does NeuroOne Medical Technologies compare to Spectral AI?

Summary

How does NeuroOne Medical Technologies compare to Sensus Healthcare?

Summary

How does NeuroOne Medical Technologies compare to Precision Optics?

Summary

How does NeuroOne Medical Technologies compare to TELA Bio?

Summary

How does NeuroOne Medical Technologies compare to Baird Medical Investment?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTC vs. The Competition

NeuroOne Medical Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroOne Medical Technologies (NMTC) Competitors

NMTC vs. MDAI, SRTS, POCI, TELA, and BDMD

How does NeuroOne Medical Technologies compare to Spectral AI?

Which has more risk & volatility, MDAI or NMTC?

Do analysts prefer MDAI or NMTC?

Does the media refer more to MDAI or NMTC?

Which has stronger earnings & valuation, MDAI or NMTC?

Do insiders and institutionals believe in MDAI or NMTC?

Is MDAI or NMTC more profitable?

Summary

How does NeuroOne Medical Technologies compare to Sensus Healthcare?

Does the media favor SRTS or NMTC?

Do analysts recommend SRTS or NMTC?

Which has better valuation and earnings, SRTS or NMTC?

Is SRTS or NMTC more profitable?

Do insiders & institutionals hold more shares of SRTS or NMTC?

Which has more risk & volatility, SRTS or NMTC?

Summary

How does NeuroOne Medical Technologies compare to Precision Optics?

Is NMTC or POCI more profitable?

Which has stronger valuation and earnings, NMTC or POCI?

Which has more risk and volatility, NMTC or POCI?

Does the media prefer NMTC or POCI?

Do analysts recommend NMTC or POCI?

Do insiders and institutionals hold more shares of NMTC or POCI?

Summary

How does NeuroOne Medical Technologies compare to TELA Bio?

Which has more volatility & risk, TELA or NMTC?

Is TELA or NMTC more profitable?

Which has preferable valuation and earnings, TELA or NMTC?

Does the media prefer TELA or NMTC?

Do analysts rate TELA or NMTC?

Do insiders & institutionals believe in TELA or NMTC?

Summary

How does NeuroOne Medical Technologies compare to Baird Medical Investment?

Is BDMD or NMTC more profitable?

Do analysts rate BDMD or NMTC?

Which has more risk and volatility, BDMD or NMTC?

Does the media favor BDMD or NMTC?

Do institutionals and insiders believe in BDMD or NMTC?

Which has stronger earnings & valuation, BDMD or NMTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMTC vs. The Competition

NeuroOne Medical Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools